OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
UNLB55

Unichem Laboratories Ltd

PharmaceuticalsVerified

Unichem Laboratories Ltd maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.19, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 2.05, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative net cash of INR 7.9 million after subtracting total debt, which may raise concerns about its short-term liquidity. In terms of profitability, Unichem Laboratories Ltd reported a return on equity (ROE) of 5.61% and a return on assets (ROA) of 3.85%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset efficiency. The company's revenue is primarily concentrated in the Indian market, with no significant international revenue disclosed in the available data. This geographic concentration may expose the company to regulatory and economic risks specific to India, such as changes in healthcare policy or currency fluctuations. Unichem Laboratories Ltd reported revenue of INR 21.1 billion in the latest period. While the company's growth trajectory is not explicitly outlined in the data, the absence of a significant increase in revenue or net income suggests a relatively stable but not rapidly growing business. The company's capital expenditures were INR 1.37 billion, indicating ongoing investment in infrastructure and operations. The company's risk profile includes a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's free cash flow of INR 1.24 billion suggests it has the capacity to fund operations and potentially return value to shareholders. Recent financial filings and transcripts do not indicate any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company's operating cash flow was negative at INR 77 million, which may be a concern for its ability to generate internal cash to fund operations.

30-day price · UNLB+2.50 (+0.7%)
Low$342.60High$402.00Close$349.35As of29 May, 00:00 UTC
Profile
CompanyUnichem Laboratories Ltd
TickerUNLB.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Unichem Laboratories Ltd is a pharmaceutical company that develops, manufactures, and markets a range of generic and branded drugs, primarily in the Indian market.

Classification. Unichem Laboratories Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Unichem Laboratories Ltd maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.19, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 2.05, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative net cash of INR 7.9 million after subtracting total debt, which may raise concerns about its short-term liquidity. In terms of profitability, Unichem Laboratories Ltd reported a return on equity (ROE) of 5.61% and a return on assets (ROA) of 3.85%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset efficiency. The company's revenue is primarily concentrated in the Indian market, with no significant international revenue disclosed in the available data. This geographic concentration may expose the company to regulatory and economic risks specific to India, such as changes in healthcare policy or currency fluctuations. Unichem Laboratories Ltd reported revenue of INR 21.1 billion in the latest period. While the company's growth trajectory is not explicitly outlined in the data, the absence of a significant increase in revenue or net income suggests a relatively stable but not rapidly growing business. The company's capital expenditures were INR 1.37 billion, indicating ongoing investment in infrastructure and operations. The company's risk profile includes a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's free cash flow of INR 1.24 billion suggests it has the capacity to fund operations and potentially return value to shareholders. Recent financial filings and transcripts do not indicate any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company's operating cash flow was negative at INR 77 million, which may be a concern for its ability to generate internal cash to fund operations.
Key takeaways
  • Unichem Laboratories Ltd has a relatively low debt-to-equity ratio of 0.19, indicating a conservative capital structure.
  • The company's return on equity (5.61%) and return on assets (3.85%) are below the industry median, suggesting underperformance in profitability.
  • The company's revenue is primarily concentrated in the Indian market, which may expose it to regulatory and economic risks specific to that region.
  • Unichem Laboratories Ltd reported a negative net cash position after subtracting total debt, which may raise concerns about its short-term liquidity.
  • The company's free cash flow of INR 1.24 billion suggests it has the capacity to fund operations and potentially return value to shareholders.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$21.11B
Gross profit$11.39B
Operating income$1.40B
Net income$1.38B
R&D
SG&A
D&A
SBC
Operating cash flow-$77.0M
CapEx-$1.37B
Free cash flow$1.24B
Total assets$35.69B
Total liabilities$11.19B
Total equity$24.51B
Cash & equivalents$7.9M
Long-term debt$4.60B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$24.51B
Net cash-$4.59B
Current ratio2.0
Debt/Equity0.2
ROA3.9%
ROE5.6%
Cash conversion-6.0%
CapEx/Revenue-6.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricUNLBActivity
Op margin6.6%7.7% medp25 -2.4% · p75 15.5%below median
Net margin6.5%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin54.0%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-6.5%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity19.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-19 08:05 UTC#a35c997f
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 21:00 UTCJob: 9cec70c7